Peroxisome proliferator-activated receptor ligands exert antineoplastic effects in hepatocellular carcinoma cells |
Chae, Myung-Jong
(Department of Internal Medicine, Kyung Hee University School of Medicine)
Shim, Jae-Jun (Department of Internal Medicine, Kyung Hee University School of Medicine) Kim, Byung-Ho (Department of Internal Medicine, Kyung Hee University School of Medicine) Hwangbo, Young (Department of Internal Medicine, Kyung Hee University School of Medicine) Lee, Young-Ju (Department of Internal Medicine, Kyung Hee University School of Medicine) Ha, Seung-Hyung (Department of Internal Medicine, Kyung Hee University School of Medicine) Jang, Jae-Young (Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea) Dong, Seok-Ho (Department of Internal Medicine, Kyung Hee University School of Medicine) Kim, Hyo-Jong (Department of Internal Medicine, Kyung Hee University School of Medicine) Chang, Young-Woo (Department of Internal Medicine, Kyung Hee University School of Medicine) Chang, Rin (Department of Internal Medicine, Kyung Hee University School of Medicine) |
1 | Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor agonists. Lancet Oncol 5:419-429, 2004 DOI ScienceOn |
2 | Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPAR. Nat Med 4:1046- 1052, 1998 DOI ScienceOn |
3 | Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, Kawaguchi T, Sasatomi K, Kimura R, Hashimoto O, Ueno T, Yano H, Kojiro M, Sata M. Involvement of p21 (WAF1/Cip1), p27 (Kip1), and p18 (INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33:1087-1097, 2001 DOI ScienceOn |
4 | Yoshizawa K, Cioca DP, Kawa S, Tanaka E, Kiyosawa K. Peroxisome proliferator-activated receptor ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 95:2243-2251, 2002 DOI ScienceOn |
5 | Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H, Mori M. A ligand for peroxisome proliferator activated receptor inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50:563-567, 2002 DOI ScienceOn |
6 | Motomura W, Takahashi N, Nagamine M, Sawamukai M, Tanno S, Kohgo Y, Okumura T. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer 108:41-46, 2004 DOI ScienceOn |
7 | Frohlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 12:291-303, 2005 DOI ScienceOn |
8 | Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR, a lipid-activated transcription factor. Cell 79:1147-1156, 1994 DOI ScienceOn |
9 | Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, Chen CS. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/ Bcl-2 functions independently of PPARgamma. Cancer Res 65:1561-1569, 2005 DOI ScienceOn |
10 | Nakata S, Yoshida T, Shiraishi T, Horinaka M, Kouhara J, Wakada M, Sakai T. 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPAR and potentiates TRAIL-induced apoptosis. Mol Cancer Ther 5:1827-1835, 2006 DOI ScienceOn |
11 | Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA, Chilton FH. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 20:1905- 1911, 1999 DOI ScienceOn |
12 | Nolte W, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol Diabetes 103:63-74, 1995 DOI ScienceOn |
13 | Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, Freeman BA. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A 102:2340-2345, 2005 |
14 | Korea National Statistical Office. The cause of the death. Avail from: http://www.nso.go.kr |
15 | McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC, Zimmerman GA, Hama K, Aoki J, Arai H, Prestwich GD. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A 100:131- 136, 2003 |
16 | Kim JR, Kim JW, Lee HS, Yoon YB, Song IS. Natural history and survival rate of chronic liver diseases in Korea: 20 years prospective analysis. Korean J Med 46:168-180, 1994 |
17 | Ray DM, Akbiyik F, Phipps RP. The peroxisome proliferator- activated receptor gamma (PPARgamma) ligands 15-deoxy- Delta12,14 -prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma- independent mechanisms. J Immunol 177: 5068-5076, 2006 DOI PUBMED |
18 | Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS. Beyond peroxisome proliferator-activated receptor signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 13:401-413, 2006 DOI ScienceOn |
19 | Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Ichite N, Singh M. 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs 18:65-78, 2007 DOI ScienceOn |
20 | Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. Ligand for peroxisome proliferator-activated receptor (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58:3344-3352, 1998 PUBMED |
21 | Bae MA, Rhee H, Song BJ. Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol Lett 139:67-75, 2003 DOI ScienceOn |
22 | Rumi MA, Sato H, Ishihara S, Kawashima K, Hamamoto S, Kazumori H, Okuyama T, Fukuda R, Nagasue N, Kinoshita Y. Peroxisome proliferator-activated receptor ligand- induced growth inhibition of human hepatocellular carcinoma. Br J Cancer 84:1640-1647, 2001 DOI ScienceOn |
23 | Han S, Roman J. Peroxisome proliferator-activated receptor : a novel target for cancer therapeutics? Anticancer Drugs 18:237-244, 2007 DOI ScienceOn |
24 | Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 50:658-664, 2002 DOI ScienceOn |
25 | El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33:62-65, 2001 DOI ScienceOn |
26 | Kojima K, Shimada T, Mitobe Y, Yoshiura K, Hiraishi H, Terano A. Effect of PPARgamma ligands on the viability of gastric epithelial cells. Aliment Pharmacol Ther 16(Suppl 2):67-73, 2002 DOI ScienceOn |
27 | Ray DM, Bernstein SH, Phipps RP. Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. Clin Immunol 113:203-213, 2004 DOI ScienceOn |